EN DE
Watch OliX PharmaceuticalsInc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

OliX PharmaceuticalsInc (226950) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of OliX PharmaceuticalsInc stock KRW 46,096, price KRW 81,800, that is 43.6% below the price, quality 32 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7226950004

OP OliX PharmaceuticalsInc logo Thin data Nov 10, 2026

OliX PharmaceuticalsInc

226950 · KQ
Very expensive, weak quality

Our calculation puts a fair price 44% below what the stock costs today.

Low debt
Mixed Growth (revenue 5y +42.8 %/yr in KRW)
Revenue last quarter 58% below a year ago.
Fair value 46,096 KRW · Strongly overvalued
Quality 32/100
Loss-making · -102.9% net margin (TTM)
Negative free cash flow
Trails peers (2/8)
Narrow moat 9/100
Thin data
Estimate
Watch OliX PharmaceuticalsInc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

207,000 KRW 8,750 KRW Fair Value 46,096 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 8,750 KRW – 207,000 KRW · fair‑value band 34,572 KRW – 57,620 KRW · the 81,800 KRW price screens above the 46,096 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow OliX PharmaceuticalsInc in your weekly email

Every Wednesday you see whether OliX PharmaceuticalsInc is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases.

Show moreShow less

The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis.

The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia.

The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.

Stock analysis

OliX PharmaceuticalsInc (226950) currently trades at 81,800 KRW, while our estimate is 46,096 KRW, 44% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 34,572 KRW (bear) to 57,620 KRW (bull), the price of 81,800 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

OliX PharmaceuticalsInc reported revenue of 14.7B KRW in FY2025 versus 3.7B KRW in FY2021, a compound +41.3%/yr. Reported net income was −15.7B KRW in FY2025.

Key figures

Market cap 1.8T KRW (≈ $1.4B) Small · EPS (TTM) −616.70 KRW · Net margin −103% · Return on equity −10.8% · Return on assets (EBIT) −26.3% (5-year average) · Operating margin −533% · Revenue (TTM) 13.6B KRW · Revenue growth (YoY) −58.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 60% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −44%, 226950 screens richer than that median.

Fair Value

Bear 34,572 KRW Fair Value 46,096 KRW Bull 57,620 KRW
Price 81,800 KRW · Downside -43.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 76
Debt, balance sheet and risk of trouble
Investment 24
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 11
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.8%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+49.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−656.4% (2020) → −204.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

226950 screens overvalued: fair value 44% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare OliX PharmaceuticalsInc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Below median
Fair Value upside −43.6% · Bottom 25%
Profitability
Return on assets −8.1% · Above median
Net margin (12 months) −102.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −58.0% · Bottom 25%
Balance sheet
Debt / equity 0.12× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 12.18× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)94 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 226950
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 226950
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 226950
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 226950
argenx SE ARGX $971.55 $908.40 −7% vs 226950
CSL Limited CSL A$201.68 A$181.40 −10% vs 226950
Moderna, Inc MRNA $250.83 $158.70 −37% vs 226950
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 226950
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 226950
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 226950

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

OliX PharmaceuticalsInc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "OliX PharmaceuticalsInc Fair Value". https://www.fairvalue-calculator.com/stock/226950

Frequently asked questions

Is OliX PharmaceuticalsInc (226950) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 46,096 KRW versus a price of 81,800 KRW, about 44% lower (overvalued).
What is the fair value of 226950?
Our estimate for OliX PharmaceuticalsInc is 46,096 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 81,800 KRW.
What is the quality score of 226950?
OliX PharmaceuticalsInc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for OliX PharmaceuticalsInc (226950)?
Our calculated price target is the estimate of 46,096 KRW (as of Nov 10, 2026). Cautious scenario 34,572 KRW, optimistic scenario 57,620 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the OliX PharmaceuticalsInc stock forecast for 2026?
Our estimate puts fair value at 46,096 KRW, about 44% lower versus a price of 81,800 KRW (overvalued). Cautious scenario 34,572 KRW, optimistic scenario 57,620 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of OliX PharmaceuticalsInc (226950)?
OliX PharmaceuticalsInc reported trailing-twelve-month revenue of about 13.6B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of OliX PharmaceuticalsInc (226950)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For OliX PharmaceuticalsInc it is 46,096 KRW per share (as of Nov 10, 2026), against a price of 81,800 KRW.
Is OliX PharmaceuticalsInc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 226950 trades above its calculated fair value: price 81,800 KRW, fair value 46,096 KRW, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 226950?
No. The price is what the market pays today (81,800 KRW); the fair value is what the company's own numbers justify (46,096 KRW). For OliX PharmaceuticalsInc the two are 35,704 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is OliX PharmaceuticalsInc worth?
The market values OliX PharmaceuticalsInc at about 1.8T KRW (market capitalisation, as of Nov 10, 2026). Per share that is 81,800 KRW; our models calculate a fair value of 46,096 KRW per share.
What do the bullish and bearish scenarios say about 226950?
Our models span a range for OliX PharmaceuticalsInc: cautious scenario 34,572 KRW, base 46,096 KRW, optimistic 57,620 KRW per share (as of Nov 10, 2026, price 81,800 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of OliX PharmaceuticalsInc (226950)?
Balance-sheet figures for OliX PharmaceuticalsInc (as of Nov 10, 2026): return on equity −10.8%, debt of 0.12 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is 226950 from its 52-week high?
OliX PharmaceuticalsInc trades at 81,800 KRW, about 60% below its 52-week high of 207,000 KRW and 10% above the low of 74,100 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 46,096 KRW is for.
Which stocks are comparable to OliX PharmaceuticalsInc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is OliX PharmaceuticalsInc stock attractive at the current price?
The data as of Nov 10, 2026: price 81,800 KRW, calculated fair value 46,096 KRW (−44%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. OliX PharmaceuticalsInc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of OliX PharmaceuticalsInc (226950)?
The closing price on Nov 10, 2026 was 81,800 KRW. Our estimate is 46,096 KRW, about 44% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with OliX PharmaceuticalsInc right now?
The price sits above even our optimistic bull case (57,620 KRW). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of OliX PharmaceuticalsInc

How large is the market capitalisation of OliX PharmaceuticalsInc (226950)?
The market capitalisation of OliX PharmaceuticalsInc is 1.8T KRW (≈ $1.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of OliX PharmaceuticalsInc (226950)?
Earnings per share at OliX PharmaceuticalsInc are −616.70 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of OliX PharmaceuticalsInc (226950)?
The net margin of OliX PharmaceuticalsInc is −103% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of OliX PharmaceuticalsInc (226950)?
The return on equity (ROE) of OliX PharmaceuticalsInc is −10.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of OliX PharmaceuticalsInc (226950)?
On an EBIT basis the return on assets of OliX PharmaceuticalsInc is −26.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of OliX PharmaceuticalsInc (226950)?
The operating margin of OliX PharmaceuticalsInc is −533% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at OliX PharmaceuticalsInc (226950)?
Revenue at OliX PharmaceuticalsInc is growing −58.0% versus a year earlier (3y avg +16.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at OliX PharmaceuticalsInc (226950)?
Earnings per share at OliX PharmaceuticalsInc are growing −41.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does OliX PharmaceuticalsInc (226950) generate?
The free cash flow of OliX PharmaceuticalsInc is −17.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does OliX PharmaceuticalsInc (226950) carry?
The net debt of OliX PharmaceuticalsInc is 15.7B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch OliX PharmaceuticalsInc in the live analysis

One click puts OliX PharmaceuticalsInc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.